Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
- Author:
Taku KOBAYASHI
1
;
Tadakazu HISAMATSU
;
Yasuo SUZUKI
;
Haruhiko OGATA
;
Akira ANDOH
;
Toshimitsu ARAKI
;
Ryota HOKARI
;
Hideki IIJIMA
;
Hiroki IKEUCHI
;
Yoh ISHIGURO
;
Shingo KATO
;
Reiko KUNISAKI
;
Takayuki MATSUMOTO
;
Satoshi MOTOYA
;
Masakazu NAGAHORI
;
Shiro NAKAMURA
;
Hiroshi NAKASE
;
Tomoyuki TSUJIKAWA
;
Makoto SASAKI
;
Kaoru YOKOYAMA
;
Naoki YOSHIMURA
;
Kenji WATANABE
;
Miiko KATAFUCHI
;
Mamoru WATANABE
;
Toshifumi HIBI
Author Information
- Publication Type:Review
- Keywords: Crohn disease; Colitis, ulcerative; Prognosis; Colorectal neoplasms; Consensus
- MeSH: Asian Continental Ancestry Group; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms; Consensus; Crohn Disease; Disease Management*; Disease Progression; Early Intervention (Education); Epidemiology; Expert Testimony; Gastrointestinal Tract; Hospitalization; Humans; Inflammatory Bowel Diseases*; Japan*; Prevalence; Prognosis
- From:Intestinal Research 2018;16(2):168-177
- CountryRepublic of Korea
- Language:English
- Abstract: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
